Lipitor Diabetes National Class Action
QC Mar 24, 2014 [en]
Motion for Authorization
CONSUMER LAW GROUP has launched a Canada-wide class action lawsuit against the maker of Lipitor, manufactured by Pfizer, on behalf of individuals who developed type 2 diabetes after taking statin drug.
Several scientific studies published in medical journals have confirmed that there is a significant increased risk of developing type 2 diabetes when taking Lipitor and that the risk is strongest amongst post menopausal women.
Until Health Canada's September 4, 2012 change, Lipitor's label had never warned Canadian patients of any potential relationship between changes in blood sugar levels and taking Lipitor.
The class action lawsuit identifies the group of affected persons as:
All persons residing in Canada who have taken and/or purchased the drug, ATORVASTATIN CALCIUM (sold under the brand name LIPITOR) since March 5th 1997, and their successors, assigns, family members, and dependants, or any other group to be determined by the Court.
If you or a member of your family have used the statin drugs Lipitor or Crestor and were subsequently diagnosed with type 2 diabetes, and you wish more information on potential compensation or to be kept advised of the status of the Lipitor or Crestor Drug Side Effects Class Action litigation or any resulting compensation from the Lipitor or Crestor Drug Side Effects Lawsuit in Canada, Quebec or Ontario, please provide your contact information to our law firm using the below form.
IF YOU WISH TO JOIN THE CLASS ACTION OR TO SIMPLY GET MORE INFORMATION, PLEASE COMPLETE THE FORM BELOW. Please note that providing your information creates no financial obligation for you. You are not charged any fee or cost for joining this class action. Our law firm is paid a contingency fee from the compensation recovered, only if the class action is successful. All information contained in this transmission is confidential and Consumer Law Group agrees to protect this information against unauthorized use, publication or disclosure.